Lesson
Pregnancy Context and Medication Decisions
Medication use in pregnancy is a benefit and risk decision for two linked patients, not a search for a drug with zero uncertainty.
- Gestational age
- Maternal disease
- Baseline risk
- Shared decisions
- Preconception review
Confirm indication, exposure, gestational age, and clinical urgency
Include maternal relapse, fetal effects, and baseline pregnancy risk
State evidence, uncertainty, goals, and follow-up
Establish the timeline
Document the best obstetric estimate of gestational age, trimester, exposure dates, dose, route, duration, and indication. Gravidity and parity describe pregnancy history, but they do not replace the current gestational timeline.
Compare treatment with no treatment
Every pregnancy has a baseline risk of loss and congenital conditions. A useful assessment compares the best treatment options with the expected harm of untreated or undertreated maternal disease.
Review before and during pregnancy
Reconcile prescriptions, nonprescription products, supplements, alcohol, nicotine, and other exposures. Stop, substitute, or continue therapy only after considering withdrawal, relapse, and disease control.
Quick check
Lesson
Maternal Physiology and Pharmacokinetics
Pregnancy changes plasma volume, protein binding, body composition, hepatic activity, renal filtration, and gastrointestinal function in drug-specific ways.
- Plasma volume
- Albumin
- GFR
- CYP activity
- Free drug
Distribution volume can expand while albumin and total levels fall
Renal clearance often rises while hepatic effects remain enzyme specific
A pregnancy-adjusted dose can become excessive postpartum
Distribution changes
Plasma volume and total body water expand, body fat can increase, and albumin decreases. Hydrophilic drugs can have a larger apparent distribution volume, while lower binding can reduce total concentrations without a proportional fall in free drug.
Clearance changes
Renal blood flow and glomerular filtration increase early in pregnancy, which can increase clearance of renally eliminated drugs. Hepatic enzyme activity changes by pathway, so metabolism does not move uniformly in one direction.
Measure the right signal
Use drug-specific targets, symptoms, organ function, and validated concentration monitoring when available. Pregnancy can alter dose needs over time, and postpartum reversal can make a pregnancy-adjusted dose excessive.
Quick check
Lesson
Placental Transfer, Structure, and Developmental Timing
Placental exposure depends on drug structure, concentration gradients, transport, protein binding, blood flow, metabolism, dose, and developmental timing.
- Passive diffusion
- Lipophilicity
- Ionization
- Protein binding
- Developmental window
Protein binding and transport also influence fetal exposure
Dose, blood flow, metabolism, and placental physiology change the gradient
Implantation, organogenesis, growth, and neonatal adaptation create distinct questions
Read the molecule
Small, lipophilic, nonionized, weakly protein-bound compounds often diffuse more readily. Large molecules may cross less efficiently, but molecular weight is not an absolute barrier because transport mechanisms and placental integrity also matter.
Separate exposure from effect
Placental transfer means fetal exposure, not automatic toxicity. Effect depends on concentration, duration, target biology, maternal and fetal genetics, and the developmental process active at the time.
Use developmental windows
Early exposure can affect implantation or loss, organogenesis is associated with structural-malformation risk, and later exposure can alter growth, organ function, adaptation at birth, or withdrawal. These are patterns, not guarantees.
Quick check
Lesson
Evidence, FDA Labeling, and Risk Communication
Current FDA prescription labeling uses narrative evidence and clinical considerations rather than the retired A, B, C, D, and X categories.
- PLLR
- Pregnancy registry
- Risk summary
- Clinical considerations
- Data limitations
Read risk summary, clinical considerations, data, and reproductive potential
Assess comparator, timing, confounding, precision, and mechanism
Separate known findings from uncertainty and background risk
Use the current label
Section 8.1 Pregnancy describes risk summary, clinical considerations, and available human or animal data. Section 8.2 Lactation addresses milk presence, effects on the breastfed child, and effects on milk production. Section 8.3 addresses reproductive potential when relevant.
Grade the evidence honestly
Randomized pregnancy safety trials are uncommon. Registries, cohorts, case-control studies, pharmacovigilance, animal data, mechanism, and background rates each answer different questions and carry different biases.
Communicate absolute meaning
State the observed outcome, comparison group, precision, exposure timing, confounding, and what remains unknown. Avoid converting absence of evidence into evidence of no risk.
Quick check
Lesson
Common Symptoms and Self-Care
Constipation, reflux, nausea, vomiting, and hemorrhoids are common, but severity, hydration, weight trajectory, bleeding, pain, and alternate diagnoses determine whether self-care is appropriate.
- Nonpharmacologic care
- Doxylamine pyridoxine
- Antacids
- Laxatives
- Red flags
Assess hydration, weight, bleeding, pain, fever, and alternate diagnoses
Use current pregnancy-compatible nonpharmacologic and medication options
Set a time to reassess and clear reasons to seek urgent care
Treat nausea systematically
Small frequent meals and trigger reduction may help. Pyridoxine can be tried first and doxylamine added when needed. Persistent vomiting, dehydration, electrolyte disturbance, weight loss, or abdominal findings require clinical assessment.
Manage reflux deliberately
Use meal timing, positional strategies, and an appropriate antacid or acid-suppressive option when needed. Avoid obsolete products and check sodium, magnesium, aluminum, calcium, renal function, and interacting-drug considerations.
Address bowel symptoms
Hydration, fiber, movement, and bulk-forming or osmotic strategies can be considered. Rectal bleeding, severe pain, obstruction symptoms, fever, or failure of conservative care changes the pathway.
Quick check
Lesson
Diabetes in Pregnancy
Preexisting diabetes and gestational diabetes require coordinated nutrition, monitoring, medication, fetal assessment, and postpartum follow-up.
- Screening
- Glucose targets
- Insulin
- Placental transfer
- Postpartum testing
Interpret each reading against its time-specific target
Use insulin when targets remain unmet and teach hypoglycemia care
Reduce therapy as physiology changes and arrange OGTT plus lifelong screening
Diagnose and monitor
Evaluate for overt diabetes early when indicated and screen for gestational diabetes at 24 to 28 weeks if not already diagnosed. Common treatment targets are fasting below 95 mg/dL, one hour below 140, and two hours below 120.
Select therapy
Nutrition and behavioral treatment are foundational. Insulin is the preferred medication when targets are not met. Metformin and glyburide cross the placenta and are not first-line substitutes for insulin under ADA guidance.
Plan postpartum care
Insulin requirements can fall sharply after delivery. People with gestational diabetes need a 75 g oral glucose tolerance test at 4 to 12 weeks postpartum and lifelong screening every one to three years.
Quick check
Lesson
Hypertension, Preeclampsia, and Eclampsia
Hypertension after 20 weeks, proteinuria or end-organ findings, symptoms, fetal status, and severe-range pressure define the urgency of evaluation and treatment.
- Chronic hypertension
- Severe features
- Low-dose aspirin
- Magnesium
- Delivery planning
Use 81 mg aspirin in the recommended gestational window
Proteinuria is not required when qualifying severe features are present
Treat severe pressure, use magnesium when indicated, and coordinate delivery
Recognize the syndrome
Preeclampsia can be diagnosed without proteinuria when new hypertension is accompanied by qualifying thrombocytopenia, renal insufficiency, liver dysfunction, pulmonary edema, persistent neurologic symptoms, or visual symptoms.
Prevent when eligible
ACOG recommends 81 mg aspirin daily for high-risk patients, started between 12 and 28 weeks, optimally before 16 weeks, and continued until delivery. It can be considered when more than one moderate-risk factor is present.
Treat the emergency
Acute severe hypertension requires prompt pregnancy-appropriate therapy. Magnesium sulfate is used to prevent or treat eclamptic seizures in indicated patients. Timing of delivery depends on severity, gestational age, maternal and fetal status, and response.
Quick check
Lesson
Venous Thromboembolism and Peripartum Anticoagulation
Pregnancy and the postpartum period increase thrombosis risk while delivery and neuraxial procedures make anticoagulant timing a high-stakes coordination problem.
- VTE risk
- LMWH
- UFH
- Warfarin
- Neuraxial planning
Match prevention or treatment intensity to risk and organ function
Verify the exact dose-specific interruption interval and reversal options
Balance bleeding, thrombosis, breastfeeding, duration, and follow-up
Assess the event and risk
Symptoms suggesting deep-vein thrombosis or pulmonary embolism need urgent diagnostic evaluation. Previous VTE, thrombophilia, cesarean delivery, immobilization, obesity, and postpartum status change prophylaxis decisions.
Choose pregnancy-compatible therapy
Low-molecular-weight heparin is commonly preferred for treatment during pregnancy because it does not cross the placenta. Unfractionated heparin can be useful when rapid offset or reversal is important. Warfarin is generally avoided during pregnancy but can be compatible with breastfeeding.
Coordinate the peripartum plan
Neuraxial and delivery timing depends on drug, dose, renal function, last administration, bleeding risk, and local anesthesia protocol. Exact intervals are regimen specific and should be verified rather than memorized as one universal rule.
Quick check
Lesson
Lactation Exposure Science
Infant exposure through milk depends on maternal concentration, milk transfer, oral absorption, dose timing, milk intake, infant clearance, and the medicine's active metabolites.
- Milk to plasma ratio
- Relative infant dose
- Oral bioavailability
- Infant age
- Milk production
Binding, ionization, lipid solubility, transport, and time affect concentration
Relative infant dose estimates exposure but does not define toxicity
Prematurity, illness, and neonatal age can increase accumulation
Trace the exposure
Many drugs enter milk by passive diffusion. Lipophilicity, ionization, protein binding, molecular size, active transport, milk composition, maternal dose, and time since dose influence milk concentration.
Calculate relative infant dose
Relative infant dose compares the estimated infant dose in milk, normalized to infant weight, with the maternal weight-normalized dose. A lower value can be reassuring, but potency, toxicity, metabolites, and vulnerable infants still matter.
Account for the infant
Prematurity, neonatal age, illness, feeding volume, and immature renal or hepatic clearance can increase risk. Also assess whether a medicine reduces milk production or whether avoiding treatment threatens maternal health or feeding goals.
Quick check
Lesson
Medication Selection During Lactation
Good lactation care treats maternal disease while minimizing infant harm through drug-specific evidence, dose design, infant monitoring, and feeding support.
- LactMed
- FDA section 8.2
- Infant monitoring
- Codeine
- Shared decision
Avoid fixed class lists and use the exact product, dose, and duration
Choose a suitable drug and formulation without relying on universal feed timing
Name observable signs, maternal goals, follow-up, and an escalation route
Use drug-specific evidence
Consult NIH LactMed, current FDA labeling, specialist guidelines, and primary evidence. Broad class avoid lists become outdated and can cause unnecessary interruption of breastfeeding or undertreatment of the lactating patient.
Avoid unsafe shortcuts
FDA recommends against codeine and tramadol during breastfeeding because variable metabolism can expose an infant to serious opioid toxicity. Timing doses after feeds cannot reliably neutralize every long half-life, active metabolite, sustained-release, or high-risk medicine.
Monitor what matters
Define infant signs such as sedation, poor feeding, respiratory depression, diarrhea, rash, jaundice, irritability, or inadequate weight gain according to the drug. Include maternal response, milk supply, duration, and an escalation plan.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.